Navigation Links
NCPAP Decreases Cerebrovascular Risk in OSA Patients

Patients with sleep apnea having significantly higher serum levels of inflammatory markers, as well as lesions associated with silent brain infarction//, have an elevated risk of stroke, according to Japanese medical researchers.

The results appear in the second issue for March 2007 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Kenji Minoguchi, M.D., Ph.D., of Showa University School of Medicine in Tokyo, and nine associates studied silent brain infarction, brain tissue death from lack of blood supply, in 50 male patients with obstructive sleep apnea (OSA). The researchers also examined the effects of three months of treatment with nasal continuous positive airway pressure (nCPAP) on serum inflammatory marker levels in 24 male patients who had moderate to severe OSA.

According to the authors, the occurrence of stroke in patients with OSA is likely preceded by subclinical cerebrovascular disease, or silent brain infarction, which is detectable with brain magnetic resonance imaging (MRI). The lesions identified as silent brain infarction were either wedge-shaped or round and showed up in brain white matter on MRI scans.

"The percentage of silent brain infarction in patients with moderate to severe OSA at 25 percent was higher than that for obese control subjects at 6.7 percent, or even patients with mild OSA who had 7.7 percent," said Dr. Minoguchi.

The investigators noted that cardiovascular disease is commonly characterized by ongoing inflammatory responses that can enhance platelet activation and increase the prevalence of silent brain infarction.

Platelets are small, colorless, irregular blood cells that promote blood clotting. Two important proteins called soluble C40 ligand and soluble P-selectin are markers of platelet activation and appear to forecast future cerebrovascular events.

The researchers found that use o f nCPAP, a treatment designed to reduce the number of episodes of breathing stoppage associated with sleep apnea, significantly lowered serum levels of C-reactive protein and the levels of the two platelet-activating proteins, all associated with cerebrovascular disease.

"As a result, nCPAP may be an important treatment intervention for decreasing the cerebrovascular risk in this susceptible population of obstructive sleep apnea patients," said Dr. Minoguchi.

In an editorial on this research in the same issue of the journal, Brian J. Murray, M.D., of Sunnybrook Health Sciences Center and the University of Toronto, Canada, wrote: "The article by Drs. Minoguchi and colleagues provides further important observations on the association between stroke and obstructive sleep apnea, with significant public health implications. The authors, using brain magnetic resonance imaging, demonstrate that patients with obstructive sleep apnea have a higher incidence of so-called silent brain infarction (i.e., those devoid of obvious clinical symptoms leading to self-detection or identification by physician examination).

The well-designed and executed study excluded patients with known risk-factor co-morbidities, thereby establishing the relationship between brain infarcts and obstructive sleep apnea itself. The significance of this finding pertains not only to stroke pathophysiology, but to dementia as well."

"Clinically identified stroke represents the tip of the iceberg in terms of cerebral vascular disease by a least an order of magnitude," he continued. "Small, but strategically placed lesions in the brain can produce clinically obvious stroke. For example, a lesion of only a few millimeters in diameter that is located in the posterior limb of the inner capsule may leave a patient with devastating hemiplegia (paralysis affecting one side of the body), that would be obvious clinically. The need to prevent these types of strokes fr om developing is obvious."

"Silent infarction identified on routine neuroimaging studies, on the other hand, may occur in areas of the brain that can only be detected clinically by detailed neurophysical assessment, or perhaps not at all with currently available tests. It is hard to believe, however, that loss of brain tissue should go without consequences. The brain may reorganize functional networks to adapt to lesions and recover function. But with each subsequent stroke, the capacity to do so is diminished. This at least partially accounts for the finding that patients with stroke and obstructive sleep apnea tend to have a longer rehabilitation stay and worse functional recovery than those patients without obstructive sleep apnea."

Dr. Murray concluded: "Treating obstructive sleep apnea with continuous positive airway pressure appears to reduce the incidence of clinically obvious stroke. This study provides a novel potential mechanism for this finding. In particular, those patients with silent infarcts and sleep apnea had elevated markers of platelet activation, such as soluble CD40 ligand and soluble P-selectin. Furthermore, continuous positive airway pressure therapy for 3 months can lower such markers in this population, thereby providing a link between the white matter lesions and their pathogenesis. Treatment with continuous positive airway pressure may therefore lead to a reduced incidence of subsequent ischemic brain lesions."

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Frequent Mammograms Can Decreases The Risk of Death
2. For High BP Patients, Preventing Enlarged Heart Decreases Risk of Atrial Fibrillation
3. Protein Increase Decreases Risk of Heart Failure
4. Adhering to Clinical Guidelines Decreases Blood Clots in the Elderly
5. Rapid Flu Testing Decreases Antibiotic Use in Hospitalized Adults
6. New Surgical Technique Decreases Colorectal OR Time
7. One in Three Heart Attack Patients Have No Chest Pains
8. Amphetamines Help Recovery of Stroke Patients
9. Painkillers Do Not Shorten Dying Patients Lives
10. Patients With Filariasis More Prone To HIV Infection
11. Glivec - New Hope For CMC Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: